Physician profile
Yang Shen
NPI 1609189075
$4,399.04
in general payments reported to CMS, 2019-2025
30 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,232 · 2020: $200 · 2021: $370 · 2022: $242 · 2023: $101 · 2024: $483 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.98 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $834.03 | 2019-2025 | Tepezza, Evenity, Prolia |
| Novo Nordisk INC | $694.36 | 2019-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $316.95 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $285.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $281.04 | 2019-2021 | |
| Insulet Corporation | $248.07 | 2021-2025 | Omnipod |
| Mannkind Corporation | $235.20 | 2019-2025 | |
| Genzyme Corporation | $219.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $172.86 | 2019-2024 | |
| Dexcom, INC. | $170.62 | 2019-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $138.13 | 2019-2025 | Benlysta |
| Medtronic Minimed, INC. | $95.08 | 2019 | |
| Corcept Therapeutics | $82.10 | 2019-2025 | Korlym |
| Radius Health, INC. | $72.75 | 2019 | |
| Beta Bionics, INC. | $72.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68.50 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $49.00 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $43.69 | 2019 | |
| Lifescan, INC. | $40.16 | 2019 | |
| Merck Sharp & Dohme LLC | $40.08 | 2019 | |
| Horizon Therapeutics Plc | $39.89 | 2019-2023 | Tepezza |
| Verity Pharmaceuticals INC. | $35.49 | 2025 | Tlando |
| Medtronic, INC. | $26.77 | 2024 | Minimed 780g |
| Becton, Dickinson and Company | $25.59 | 2019 | |
| Madrigal Pharmaceuticals | $23.59 | 2024 | Resmetirom |
| Arbor Pharmaceuticals, INC. | $21.76 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.77 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.25 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yang Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.